Home › Research › Health systems and care delivery
Characteristics of Medicare Part D Beneficiaries Who Reach the Drug Benefit Threshold in Both of the First Two Years of the Part D Benefit
Elizabeth A. Bayliss, Jennifer Ellis, Thomas Delate, John F. Steiner, Marsha A. Raebel. Medical Care, 2010-02-19
Topic: Risk, prevention and care in population studies
Plain-language summary
Those who reached the DBT in both years had higher morbidity and utilization. In multivariate analyses, they were more likely than the 2006 only group to have one or more of 5 conditions (chronic pulmonary disease, dementia, depression, incontinence, and Parkinson disease), and within these conditions were more likely to use categories of trade-name medications for which there are limited available generic alternatives. Repeatedly reaching the DBT is a function of the extent and chronicity of disease burden and is characterized by conditions for which there is limited availability of generic medications, and associated common comorbidities. If these findings are confirmed, strategies at practice and policy levels may help such Medicare beneficiaries avoid unnecessary out of pocket expenditures on medications from prematurely reaching the DBT.
What this study adds
Evidence grade: Moderate
This study found that Medicare beneficiaries who repeatedly reached the drug benefit threshold were more likely to have conditions including dementia and to use trade-name medications with limited generic alternatives. It addresses medication costs in dementia but does not test any treatment, cure, or prevention for Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bayliss, E. A., Ellis, J., Delate, T., Steiner, J. F., & Raebel, M. A. (2010). Characteristics of Medicare Part D Beneficiaries Who Reach the Drug Benefit Threshold in Both of the First Two Years of the Part D Benefit. Medical Care. https://doi.org/10.1097/mlr.0b013e3181ca2824
Vancouver
Bayliss EA, Ellis J, Delate T, Steiner JF, Raebel MA. Characteristics of Medicare Part D Beneficiaries Who Reach the Drug Benefit Threshold in Both of the First Two Years of the Part D Benefit. Medical Care. 2010. doi:10.1097/mlr.0b013e3181ca2824. PMID: 20125044.
BibTeX
@article{bayliss2010-20125044,
author = {Bayliss, Elizabeth A. and Ellis, Jennifer and Delate, Thomas and Steiner, John F. and Raebel, Marsha A.},
title = {{Characteristics of Medicare Part D Beneficiaries Who Reach the Drug Benefit Threshold in Both of the First Two Years of the Part D Benefit}},
journal = {Medical Care},
year = {2010},
doi = {10.1097/mlr.0b013e3181ca2824},
pmid = {20125044},
url = {https://doi.org/10.1097/mlr.0b013e3181ca2824}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Those who reached the DBT in both years had higher morbidity and utilization.
- In multivariate analyses, they were more likely than the 2006 only group to have one or more of 5 conditions (chronic pulmonary disease, dementia, depression, incontinence, and Parkinson disease), and within these conditions were more likely to use categories of trade-name medications for which there are limited available generic alternatives.
- Repeatedly reaching the DBT is a function of the extent and chronicity of disease burden and is characterized by conditions for which there is limited availability of generic medications, and associated common comorbidities.
- If these findings are confirmed, strategies at practice and policy levels may help such Medicare beneficiaries avoid unnecessary out of pocket expenditures on medications from prematurely reaching the DBT.
Why it matters
This study found that Medicare beneficiaries who repeatedly reached the drug benefit threshold were more likely to have conditions including dementia and to use trade-name medications with limited generic alternatives. It addresses medication costs in dementia but does not test any treatment, cure, or prevention for Alzheimer's disease.
Study details
- Study designretrospective cohort
- Evidence strengthModerate
How this study scored 43/100
Published in a peer-reviewed journal, and it is a retrospective cohort study, reconstructed from past records. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Medical Care) |
| Journal's citation record | 3 / 4 | Medical Care: journal h-index 273 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A retrospective cohort study, reconstructed from past records |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 3 / 6 | Cited 6.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Marsha A. Raebel: h-index 56 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Colorado Denver: institution h-index 907 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20125044) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also tagged “palliative”
858 studies in the library carry the topic tag “palliative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.